Enterprise Value

175.8M

Cash

84.06M

Avg Qtr Burn

-9.908M

Short % of Float

8.03%

Insider Ownership

2.13%

Institutional Own.

26.85%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Iomab-B (CD45) (apamistamab-I-131) Details
Hematopoietic cell transplantation , Acute myeloid leukemia

BLA

Submission

Actimab-A + venetoclax Details
Relapsed/refractory acute myeloid leukemia

Phase 1/2

Update

Iomab-ACT (CAR-T – CD45) Details
Lymphoma, Diffuse large B cell lymphoma

Phase 1/2

Update

Actimab-A + CLAG-M Details
Relapsed/refractory acute myeloid leukemia

Phase 1

Update

Iomab-ACT (GeneTx – CD45) Details
Lymphoma, Acute radiation syndrome

Failed

Discontinued

Actimab-A + venetoclax Details
Myelodysplastic syndrome

Failed

Discontinued